Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Moore, M. M.
Right arrow Articles by Harrington-Brock, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, M. M.
Right arrow Articles by Harrington-Brock, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 14, No. 3, 261-263, May 1999
© 1999 UK Environmental Mutagen Society/Oxford University Press

Discussion Forum

Failure to adequately use positive control data leads to poor quality mouse lymphoma data assessments

Martha M. Moore1, Deborah D. Collard and Karen Harrington-Brock

Environmental Carcinogenesis Division, National Health and Environmental Effects Research Laboratory, US Environmental Protection Agency, Research Triangle Park, NC 27711, USA

The mouse lymphoma L5178Y/TK+/–-3.7.2C mutagenesis assay (MLA) is widely used to identify chemicals that are capable of inducing mutational damage (Mitchell et al., 1997Go). Mutants detected in the assay form a bimodal distribution based on colony size. More than two decades of research demonstrate that both small and large colony trifluorothymidine-resistant (TFTr) colonies are `true mutants' and that the assay detects the broad spectrum of genetic damage known to be involved in the etiology of cancer (Moore-Brown et al., 1981Go; Moore et al., 1985bGo; Applegate et al., 1990Go; Hozier et al., 1992Go). Because the assay detects mutagens that act through a variety of mechanisms, the MLA is specifically recommended by regulatory agencies for inclusion in hazard identification screening for environmental chemicals and pharmaceuticals (Dearfield et al., 1991Go; ICH3, 1996).

Because of the ability of the MLA . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
J. M. Parry
Applications and interpretation of data obtained in the mouse lymphoma tk assay
Mutagenesis, May 1, 1999; 14(3): 255 - 255.
[Full Text] [PDF]

Home page
 MutagenesisHome page
J. Cole, K. Harrington-Brock, and M. M. Moore
The mouse lymphoma assay in the wake of ICH4—where are we now?
Mutagenesis, May 1, 1999; 14(3): 265 - 270.
[Full Text] [PDF]

Home page
 MutagenesisHome page
M. M. Moore, K. Harrington-Brock, and J. Cole
Issues for conducting the microtiter version of the mouse lymphoma thymidine kinase (tk) assay and a critical review of data generated in a collaborative trial using the microtiter method
Mutagenesis, May 1, 1999; 14(3): 271 - 281.
[Full Text] [PDF]